New Generic Blood Pressure Medication Will Ease Shortages from Recalls

The new drug approval comes after the federal agency says it identified the cause of these impurities in the manufacturing process.

New-Generic-Blood-Pressure-Medication-Will-Ease-Shortages-from-Recalls


The new drug approval comes after the federal agency says it identified the cause of these impurities in the manufacturing process.

The it’s started to put new requirements into place to prevent the risk of this contamination from recurring, noting “systemic problems of supervision that could have created the conditions for quality issues to arise.”

One of those systemic problems may have to do with how pharmaceutical companies acquire the active pharmaceutical ingredients (APIs) for the medications they sell, , a board-certified doctor of internal medicine and founder of consumer advocacy website told Healthline.

Often, one or a handful of large manufacturers create large quantities of the active ingredient of a drug, which is then bought by different pharmaceutical companies to formulate with their inactive ingredients.

The problem, he said, is that “there is very little oversight for the manufacturing of the APIs or where pharmaceutical companies can purchase them. Only the final product is evaluated by the FDA.”

That means a mishap at a single manufacturer can have an outsized effect on an entire industry.

“It’s the snafus in API production that have caused most of the recent shortages and recalls of generic drugs in this country,” Belk said. “The FDA should probably look into that process a bit more closely.”


For its part, the FDA says that it’s confident this newly approved generic valsartan is free of the impurities that caused the previous recalls.

“[We] evaluated the company’s manufacturing processes and also made sure they used appropriate testing methods to demonstrate that the valsartan product approved today does not contain NDMA or NDEA,” agency officials said.

“The FDA’s assessment of the manufacturing processes for the product determined that there is no known risk for the formation of other nitrosamine impurities.”

The FDA released to manufacturers for limiting these carcinogens in valsartan manufacturing.

Moreoever, since the wave of recalls began, FDA “scientists have developed and refined novel and sophisticated testing methods specifically designed to detect and quantify the NDMA and NDEA,” the agency said in a statement.

Leave a Reply

Your email address will not be published. Required fields are marked *